PET/CT in Restaging, Prognosis, and Recurrence Detection for Malignant Melanoma

Cutaneous malignant melanoma (CMM) is one of the most aggressive forms of skin cancer, often prone to recurrence even after initial treatment. Early detection and accurate staging play a critical role in improving patient survival rates, particularly when lymph node involvement and distant metastases are present.

18F-FDG PET/CT has become an essential imaging tool for malignant melanoma, enabling accurate staging, restaging, and detection of tumor recurrence. A study published in the Egyptian Journal of Radiology and Nuclear Medicine evaluated the role of PET/CT for malignant melanoma, confirming its high sensitivity and reliability in clinical practice.

Healthcare facilities offering advanced cancer imaging can now integrate mobile PET/CT solutions from Shared Medical Services to bring state-of-the-art oncology imaging directly to their patients.

The study analyzed 50 patients with confirmed malignant melanoma between the ages of 28 and 74 (mean age: 55.94), separated into three key groups:

✅ 21 patients for initial staging
✅ 11 patients with suspected post-treatment relapse
✅ 18 patients with stage IV disease for metastasis detection

Primary Staging Results

PET/CT demonstrated strong performance in determining the extent of disease:

• • Sensitivity: 93.33%
  • Specificity: 60%
  • Overall Accuracy: 85.71%

Detecting Post-Treatment Relapse

Among patients with suspected recurrence, PET/CT achieved:

• • Sensitivity: 100%
  • Specificity: 66.66%
  • PPV: 88.88%
  • NPV: 100%
  • Accuracy: 90.90%

Metastatic Melanoma Detection

In stage IV patients, PET/CT identified distant metastases with:

• • Sensitivity: 100%
  • Specificity: 66.66%
  • Accuracy: 94.44%

Additionally, higher SUVmax and SUVmean values were significantly associated with true-positive cases, reinforcing PET/CT’s superior sensitivity and reliability in melanoma management.

• Enhanced Initial Staging: Improves accuracy for treatment planning
• Early Recurrence Detection: Enables timely intervention for relapsed cases
• Prognostic Insights: SUV metrics help assess tumor burden and treatment response
• The study confirms that PET/CT not only refines diagnosis but also provides predictive insight into patient outcomes, guiding precision oncology strategies.

Sources:
El-Shourbagy, K.H., Mashaly, E.M., Khodair, S.A. et al. – PET/CT in Restaging, Prognosis, and Recurrence in Patients with Malignant Melanoma. Egyptian Journal of Radiology and Nuclear Medicine.

Media Contact:
Blake Kenney
Senior Marketing Specialist
Shared Medical Services, Inc.
Phone: (608) 910-1332
Email: contactsms@sharedmed.com